Welcome to our dedicated page for Zimmer Biomet Holdings news (Ticker: ZBH), a resource for investors and traders seeking the latest updates and insights on Zimmer Biomet Holdings stock.
Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) is a preeminent global leader in musculoskeletal healthcare. Headquartered in Warsaw, Indiana, Zimmer Biomet has been at the forefront of advancing bone and joint health for nearly 90 years. The company designs, manufactures, and markets a comprehensive range of orthopedic implants and surgical equipment, addressing joint reconstruction, bone repair, sports medicine, spine, and dental reconstruction. Its innovative product portfolio includes the ROSA® Robotics systems for knee, hip, and shoulder replacements, and the TMINI Miniature Robotic System for total knee arthroplasty.
Zimmer Biomet's latest endeavors include the establishment of a dedicated Health Equity division in 2023, which aims to integrate health equity into the company's core strategies and operations. This division has already made significant strides by assembling a strategic advisory board and developing the Community Centered Care (C3) framework to increase patient access to quality care in underserved communities.
In addition, Zimmer Biomet has recently partnered with top pickleball organizations in the U.S., underscoring its commitment to joint health and well-being for the growing community of pickleball players. The company also announced a strategic alliance with CBRE Group, Inc. to expand orthopedic ambulatory surgery centers across the country, and a collaboration with RevelAi Health to commercialize AI-powered engagement solutions aimed at advancing value-based orthopedic care and health equity.
Financially, Zimmer Biomet has demonstrated robust performance, with first-quarter 2024 net sales amounting to $1.889 billion, a 3.2% year-over-year increase. The company continues to focus on innovation, operational excellence, and strategic partnerships to drive growth and enhance shareholder value. For more information, visit www.zimmerbiomet.com or follow them on LinkedIn and Twitter.
Zimmer Biomet Holdings (NYSE: ZBH) announced that its Chairman, President and CEO Bryan Hanson and Executive Vice President and CFO Suky Upadhyay will present at Stifel's 2021 Virtual Healthcare Conference on November 17, 2021, at 10:40 a.m. Eastern Time. Investors can access a live webcast of the presentation through Zimmer Biomet's Investor Relations website. Zimmer Biomet is a global leader in medical technology, focused on enhancing mobility and health through innovative products and technologies.
Zimmer Biomet Holdings, Inc. (ZBH) will host its third quarter earnings conference call on November 4, 2021, at 8:30 a.m. ET, with a news release available at 6:30 a.m. ET. The call can be accessed on the company’s Investor Relations website and will feature digital recording availability from November 4 to December 31, 2021. Zimmer Biomet is recognized for its innovative medical technology aimed at enhancing patient mobility and healthcare quality.
Zimmer Biomet Holdings (NYSE: ZBH) announced key leadership appointments for its planned spin-off company, ZimVie, targeting the Spine and Dental businesses. Richard J. Heppenstall joins as Executive Vice President and CFO, bringing over 25 years of finance experience in the medtech sector. The spin-off is on track for mid-2022, aiming to enhance resource allocation and market leadership. The new leadership team includes seasoned professionals across various functions to drive ZimVie’s success post-separation.
Zimmer Biomet Holdings has declared a quarterly cash dividend of $0.24 per share for the third quarter of 2021. This dividend will be payable on October 29, 2021 to shareholders on record as of September 30, 2021. The company, a leader in medical technology, is known for its innovative solutions aimed at improving health and mobility. Zimmer Biomet operates globally, contributing to advancements in patient care through integrated digital and robotic technologies.
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) announced four presentations at the AAOS 2021 Annual Meeting showcasing the clinical value of mymobility with Apple Watch. This remote care management platform aids healthcare professionals in supporting patients pre- and post-orthopedic procedures. Initial findings from the ongoing mymobility Clinical Study suggest that patients using the platform experience similar outcomes to traditional care, potentially lowering postoperative costs. The conference is taking place from August 31 to September 3, 2021 in San Diego.
Zimmer Biomet Holdings (ZBH) announced that Chairman Bryan Hanson and CFO Suky Upadhyay will present at Baird's 2021 Virtual Global Healthcare Conference on September 14, 2021, at 10:50 a.m. ET. A live webcast of the presentation can be accessed via Zimmer Biomet's Investor Relations website. The company specializes in medical technology, focusing on enhancing patient mobility through innovative products and digital technologies. Zimmer Biomet operates in over 25 countries, with sales in more than 100 countries, and boasts over 90 years of industry experience.
Zimmer Biomet Holdings (NYSE: ZBH) has received FDA 510(k) clearance for its ROSA® Hip System, enhancing its robotic surgical portfolio. This system aids in robotically-assisted direct anterior total hip replacement, offering surgeons real-time data and control over surgical procedures. ROSA Hip integrates with ZBEdge and mymobility® technologies to improve patient outcomes and streamline surgical workflows. Designed for compatibility with various implant systems, it aims to enhance procedural efficiency and mitigate intra-operative variability.
Zimmer Biomet Holdings announced six key data presentations at the upcoming American Academy of Orthopaedic Surgeons (AAOS) 2021 Annual Meeting scheduled for August 31 to September 3 in San Diego. Highlights include a podium presentation of the investigational Persona IQ smart knee implant and three posters detailing the clinical utility of the mymobility remote care management platform. The company is set to showcase its latest technologies, including the ROSA Hip, which is currently under FDA review, as part of its ZBEdge Connected Intelligence suite.
Zimmer Biomet Holdings reported second-quarter 2021 net sales of $2.027 billion, a remarkable 65.3% increase from the previous year. Net earnings reached $141.9 million ($0.67 per share) with adjusted diluted EPS at $1.90. Compared to pre-pandemic Q2 2019, sales are up 1.9%. The company anticipates continued growth despite ongoing COVID-19 pressures. Zimmer Biomet has also updated its full-year 2021 guidance, projecting revenue growth of 14.5% - 16.5% and adjusted diluted EPS of $7.65 - $7.95.
ZBH will host its second quarter earnings conference call on August 3, 2021, at 8:30 a.m. ET. The financial results will be released earlier that day at 6:30 a.m. ET. Investors can access the live audio webcast on Zimmer Biomet's Investor Relations website, which will also be archived for later replay. U.S. participants can join the call by dialing (888) 312-9837 and entering the conference ID 7278985. This conference call follows Zimmer Biomet's ongoing commitment to transparency and communication with its investors.
FAQ
What is the current stock price of Zimmer Biomet Holdings (ZBH)?
What is the market cap of Zimmer Biomet Holdings (ZBH)?
What does Zimmer Biomet do?
Where is Zimmer Biomet headquartered?
What are Zimmer Biomet's latest innovations?
What is Zimmer Biomet's focus on health equity?
How did Zimmer Biomet perform financially in the first quarter of 2024?
What are Zimmer Biomet's partnerships?
What is the ROSA® Robotics system?
What is the Community Centered Care (C3) framework?
What is Zimmer Biomet's role in pickleball?
How does Zimmer Biomet contribute to innovation in healthcare?
